Literature DB >> 8721277

Changes in vancomycin pharmacokinetics during treatment.

L Pou1, M Rosell, R Lopez, C Pascual.   

Abstract

Using data gathered in routine monitoring, the pharmacokinetics of vancomycin during the first 10 days of treatment were compared with the pharmacokinetics after 10 days of treatment in 46 adult patients with normal renal function, ages 17-85 years old (mean +/- SD: 50.8 +/- 17.5). The mean time from initiation of treatment to the first sample determination was 5.5 days, and the mean time to the second determination was 13.4 days. Statistical differences between the two periods were observed for all pharmacokinetic parameters, except for the steady-state distribution volume. After 10 days of treatment, the mean +/- SD of the vancomycin clearance and elimination rate constant decreased from 1.31 +/- 0.82 to 1.13 +/- 0.72 ml/kg/min (p = 0.0044) and from 0.13 +/- 0.08 to 0.10 +/- 0.06 h-1 (p = 0.091), respectively. The half-life (t1/2) increased from 8.01 +/- 6.82 to 10.02 +/- 8.00 h (p = 0.012). The median percentage of the increment of t1/2 was 9.4%. The increase in t1/2 was > 50% in 12 patients and > 100% in nine cases. No association was found between the increment of t1/2 and the cumulative vancomycin dose. Frequent monitoring of serum vancomycin seems indicated, given the risk of decreased elimination during prolonged treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721277     DOI: 10.1097/00007691-199604000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function.

Authors:  O Rodriguez Colomo; F Álvarez Lerma; M I González Pérez; J-M Sirvent; M García Simón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

2.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.

Authors:  Matthew P Rowan; Krista L Niece; Julie A Rizzo; Kevin S Akers
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-02-01       Impact factor: 4.730

4.  Vancomycin administration: the impact of multidisciplinary interventions.

Authors:  R K Crowley; F Fitzpatrick; D Solanki; S FitzGerald; H Humphreys; E G Smyth
Journal:  J Clin Pathol       Date:  2007-02-09       Impact factor: 3.411

5.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Authors:  Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

Review 6.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.